Moderna (MRNA) is adjusting to the new pace of demand for COVID-19 vaccines in 2022, with a strong outlook on sales globally, though it still faces some hurdles in the U.S. market.
That’s according to CEO Stéphane Bancel, who said the company has already deals for $21 billion worth of doses for the year — mostly from global buyers.Meanwhile, the Congressional budget still does not have funding for booster doses for fall, even as health experts warn of a potential surge. But Moderna remains confident the U.S. government will come through.
“None of us has managed the transition from a pandemic to an endemic setting, for obvious reasons,” Bancel told Yahoo Finance. And waning protection — whether from vaccination or natural infection — will leave many people unprotected or under-protected by fall, Bancel and other executives said on an earnings call Wednesday.